Disease · MONDO_0002083
Richter transformation
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Richter transformation. Diseases, record MONDO_0002083. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002083
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Richter syndrome, Richter's syndrome, Richter's transformation, chronic lymphocytic leukemia with Richter transformation, chronic lymphocytic leukemia/small lymphocytic lymphoma with Richter transformation
- Open Targets
Drugs53
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 3 | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 10 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| VINCRISTINE | CHEMBL90555 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| PIRTOBRUTINIB | CHEMBL4650485 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| DOXORUBICIN HYDROCHLORIDE | CHEMBL359744 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| VENETOCLAX | CHEMBL3137309 | Small molecule | Phase 2 | ClinicalTrials.gov | 10 | 10 | 10 | Drugs and targets |
| IBRUTINIB | CHEMBL1873475 | Small molecule | Phase 2 | ClinicalTrials.gov | 8 | 8 | 7 | Drugs and targets |
| NIVOLUMAB | CHEMBL2108738 | Antibody | Phase 2 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| OBINUTUZUMAB | CHEMBL1743048 | Antibody | Phase 2 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
1 to 10 of 53
See all 53 drugsTargets53
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| MS4A1 | B-lymphocyte antigen CD20 | 8 | B-lymphocyte antigen CD20 binding agent | Phase 3 | https://conductscience.org/library/genes/931 | Drugs and targets |
| BTK | Tyrosine-protein kinase BTK | 5 | Tyrosine-protein kinase BTK inhibitor | Phase 3 | https://conductscience.org/library/genes/695 | Drugs and targets |
| CD3D | T cell surface glycoprotein CD3 | 5 | T cell surface glycoprotein CD3 binding agent; T cell surface glycoprotein CD3 cross-linking agent | Phase 2 | https://conductscience.org/library/genes/915 | Drugs and targets |
| CD3E | T cell surface glycoprotein CD3 | 5 | T cell surface glycoprotein CD3 binding agent; T cell surface glycoprotein CD3 cross-linking agent | Phase 2 | https://conductscience.org/library/genes/916 | Drugs and targets |
| CD3G | T cell surface glycoprotein CD3 | 5 | T cell surface glycoprotein CD3 binding agent; T cell surface glycoprotein CD3 cross-linking agent | Phase 2 | https://conductscience.org/library/genes/917 | Drugs and targets |
| CD19 | B-lymphocyte antigen CD19 | 4 | B-lymphocyte antigen CD19 binding agent; B-lymphocyte antigen CD19 cross-linking agent | Phase 2 | https://conductscience.org/library/genes/930 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 3 | Programmed cell death 1 ligand 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 3 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 3 | Programmed cell death protein 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| TOP2A | DNA topoisomerase 2-alpha | 3 | DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor | Phase 3 | https://conductscience.org/library/genes/7153 | Drugs and targets |
1 to 10 of 53
See all 53 targetsTrials52
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01607892 | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer | Phase 1 | 286 | 2021-04-01 | Hematological Malignancies | SELINEXOR | Its record names the disease | ClinicalTrials.gov |
| NCT02329847 | A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies | Phase 1/2 | 144 | 2023-06-15 | Hematologic Neoplasms | IBRUTINIB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00472849 | Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias | Phase 1/2 | 92 | 2013-11-26 | Richter's Transformation, Leukemia | CYTARABINE, FLUDARABINE, OXALIPLATIN, RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02576990 | Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) | Phase 2 | 80 | 2020-06-24 | Mediastinal Large B-cell Lymphoma, Richter Syndrome | PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00452374 | Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL | Phase 1/2 | 48 | 2011-08-29 | Leukemia | CYTARABINE, FLUDARABINE, OXALIPLATIN, RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02420912 | Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation | Phase 2 | 37 | 2024-03-20 | Loss of Chromosome 17p, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Richter Syndrome | IBRUTINIB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02138786 | Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation | Phase 2 | 27 | 2020-02-11 | Richter's Transformation | SELINEXOR | Its record names the disease | ClinicalTrials.gov |
| NCT05537766 | Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies | Phase 2 | 19 | 2026-03-10 | Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt Lymphoma, Relapsed/Refractory Hairy Cell Leukemia | BREXUCABTAGENE AUTOLEUCEL, CYCLOPHOSPHAMIDE, FLUDARABINE | Its record names the disease | ClinicalTrials.gov |
| NCT00413478 | 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia | Phase 2 | 9 | 2015-06-30 | Chronic Lymphocytic Leukemia, Leukemia | AZACITIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT03121534 | Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation | Phase 2 | 9 | 2023-02-17 | Hematopoietic/Lymphoid Cancer, Richter's Transformation | BLINATUMOMAB, IBRUTINIB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 52
See all 52 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| OFAR (Phase I) vs OFAR MTD (Phase II): serious adverse events | 8 of 12 | 15 of 78 | 90 | NCT00472849 | Trial comparisons |
| Pembrolizumab: Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) vs Pembrolizumab: Relapsed or Refractory Richter Syndrome (rrRS): deaths from any cause | 30 of 56 | 19 of 24 | 80 | NCT02576990 | Trial comparisons |
Pembrolizumab: Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) vs Pembrolizumab: Relapsed or Refractory Richter Syndrome (rrRS): Number of Participants Who Discontinued Study Drug Due to an AE | 6 of 53 | 4 of 23 | 76 | NCT02576990 | Trial comparisons |
Pembrolizumab: Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) vs Pembrolizumab: Relapsed or Refractory Richter Syndrome (rrRS): Number of Participants Who Experienced an Adverse Event (AE) | 50 of 53 | 23 of 23 | 76 | NCT02576990 | Trial comparisons |
| Pembrolizumab: Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) vs Pembrolizumab: Relapsed or Refractory Richter Syndrome (rrRS): serious adverse events | 14 of 53 | 15 of 23 | 76 | NCT02576990 | Trial comparisons |
Papers from its trials22
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002083
GET https://conductscience.org/api/diseases/v1/MONDO_0002083/drugs?page=2